During the previous funding period of this grant we made two conceptually distinct but important observations. First, we found that the endocytic and post-endocytic trafficking of opioid receptors is critically important for the development of tolerance and dependence to opioid drugs. Second, we demonstrated that opioid receptors heterodimerize to form a unique target for a heterodimer-selective agonist. Here we will follow up on both of these observations by examining how receptor pharmacology and trafficking are altered by coexpression/heterodimerization of the opioid receptors with a focus on heterodimers containing the delta opioid receptor (DOR). Two distinct pharmacologically-defined subtypes of DOR have been described, although only a single gene has been identified. Although there are many explanations for this finding, one possibility is that co-expression or heterodimerization of the DOR with other opioid receptors alters the pharmacology to produce unique opioid receptor subtypes. We will examine how DOR subtype pharmacology is altered by deletion of individual opioid receptor types. In addition, we propose that the constellation of opioid receptor subtypes or heterodimers is altered following chronic morphine administration and the development of tolerance and dependence, possibly as a consequence of alterations in receptor trafficking. Changes in the distribution of opioid receptor subtypes or heterodimers could provide novel targets for the prevention or treatment of opioid tolerance and dependence. In addition, it is possible that certain opioid receptor subtypes or heterodimers are expressed in a tissue-selective manner, a gender-specific manner, or in a disease state-specific manner (for example in chronic pain states or following prolonged use of opiate drugs). Thus targeting these subtypes or heterodimers could provide improved therapeutic utility.

Public Health Relevance

Although opioids are among the most potent analgesics available in human medicine their utility is limited by side effects including respiratory suppression, tolerance and dependence. Most opioid drugs administered systemically target multiple opioid receptors, which could contribute to these side effects. Opioid receptor subtypes and/or heterodimers, that are more limited in their expression could provide analgesic benefits without the side effects. Little is know regarding the distribution and trafficking of opioid receptor subtypes and heterodimers. In addition, it is unknown how this may change with chronic opioids. We propose that opioid receptor subtypes and/or heterodimers could provide novel targets for the treatment of chronic pain. Page PAGE ?2

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA015232-06A2
Application #
7736044
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Lin, Geraline
Project Start
2002-04-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
6
Fiscal Year
2009
Total Cost
$327,200
Indirect Cost
Name
Ernest Gallo Clinic and Research Center
Department
Type
DUNS #
173995366
City
Emeryville
State
CA
Country
United States
Zip Code
94608
Johnson, Tyler A; Milan-Lobo, Laura; Che, Tao et al. (2017) Identification of the First Marine-Derived Opioid Receptor ""Balanced"" Agonist with a Signaling Profile That Resembles the Endorphins. ACS Chem Neurosci 8:473-485
Milan-Lobo, Laura; Enquist, Johan; van Rijn, Richard M et al. (2013) Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism. PLoS One 8:e58362
van Rijn, Richard M; Harvey, Jessica H; Brissett, Daniela I et al. (2013) Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling. J Pharmacol Exp Ther 344:179-88
Harvey, Jessica H; van Rijn, Richard M; Whistler, Jennifer L (2013) A FLIPR assay for evaluating agonists and antagonists of GPCR heterodimers. Methods Mol Biol 995:43-54
van Rijn, Richard M; Defriel, Julia N; Whistler, Jennifer L (2013) Pharmacological traits of delta opioid receptors: pitfalls or opportunities? Psychopharmacology (Berl) 228:1-18
Whistler, Jennifer L (2012) Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 121:189-204
van Rijn, Richard M; Brissett, Daniela I; Whistler, Jennifer L (2012) Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists. Drug Alcohol Depend 122:156-9
Brissett, D I; Whistler, J L; van Rijn, R M (2012) Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes. Eur J Pain 16:327-37
van Rijn, Richard M; Brissett, Daniela I; Whistler, Jennifer L (2012) Emergence of functional spinal delta opioid receptors after chronic ethanol exposure. Biol Psychiatry 71:232-8
Enquist, Johan; Kim, Joseph A; Bartlett, Selena et al. (2011) A novel knock-in mouse reveals mechanistically distinct forms of morphine tolerance. J Pharmacol Exp Ther 338:633-40

Showing the most recent 10 out of 28 publications